If excessive marked redness, peeling, or discomfort occurs at the application site, TRI-LUMA should be used less frequently or discontinued altogether. This will not have any systemic consequence as the percutaneous absorption of the active ingredients in Tri-Luma into the systemic circulation in healthy volunteers (N=59) was to be found minimal following 8 weeks of daily application of 1g or 6g of Tri-Luma. A symptomatic treatment might be prescribed as appropriate.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
